Viracta Therapeutics, Inc.

VIRX

Viracta Therapeutics, Inc.

VIRX

Insider Sentiment (TTM):

Last Purchase:2023-12-01Last Sale:2024-02-27Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2024-12-31Institutional Shares Owned:3,391,371Shares Outstanding:39,574,070Institutional Ownership Pct.:8.57%

Earnings Market Reaction:

Filing Date:2024-11-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	13	14	12	12	13	14	18	37	23	82	92	104
Short Term Investments	8	16	28	41	50	59	62	54	54	2	-	0
Prepaid Expense And Other Assets Current	1	1	1	1	1	2	3	3	3	3	3	2
Assets Current	22	31	41	55	64	75	83	94	80	86	95	105
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	0	0	0	0	0	0	1	0	0	0	1	1
Other Assets Noncurrent	0	0	0	1	1	2	2	2	2	2	2	2
Assets	22	31	41	57	66	77	86	96	82	89	98	109
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	2	1	2	2	2	3	2	3	2	2	3	3
Accrued Liabilities Current	10	9	9	10	9	7	7	7	7	5	4	6
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-	0
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Other Long Term Debt Current	-	-	-	25	25	4	2	0	-	-	-	-
Debt Current	17	19	19	-	-	-	-	-	-	-	-	-
Liabilities Current	29	29	30	38	36	15	12	10	9	7	8	9
Long Term Debt Noncurrent	-	-	-	0	0	21	23	25	5	5	5	5
Operating Lease Liability Noncurrent	-	-	-	-	-	0	0	0	0	0	0	0
Other Long Term Debt	-	-	-	-	-	-	-	-	0	-	-	-
Liabilities	29	29	30	38	36	36	-	35	-	-	-	-
Stockholders Equity
Preferred Stock Value	0	5	5	5	5	5	5	5	5	5	5	5
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	289	282	281	279	277	275	273	271	267	258	256	255
Accumulated Other Comprehensive Income Loss Net Of…	0	-0	-0	0	-0	-0	-0	-0	-0	-	-	0
Retained Earnings Accumulated Deficit	-295	-285	-275	-266	-252	-240	-227	-215	-205	-187	-176	-166
Stockholders Equity	-7	3	11	18	30	41	51	61	68	77	86	94
Liabilities And Stockholders Equity	22	31	41	57	66	77	86	96	82	89	98	109
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	400	400	400	400	400	400	400	400	400	400	400	400
Common Stock Shares Issued	40	39	39	39	39	39	38	38	38	38	37	37
Shares Outstanding	40	39	39	39	39	39	38	38	38	38	37	37

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2024	-15.15%	-34.10%	-41.78%	-36.58%	-38.68%	-48.84%	0.25%	41.95%	-3.56%	-	-	-
2023	37.38%	31.78%	37.38%	-6.38%	-43.90%	-51.65%	-29.05%	-17.30%	-21.63%	25.91%	2.25%	-9.27%
2022	3.90%	58.87%	43.72%	26.51%	23.05%	6.05%	-36.05%	-55.96%	-36.05%	-16.57%	-42.86%	-16.00%
2021	-	-	-	-	-	-	-	-	-	59.21%	-19.41%	-21.05%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31
Liquidity Ratios
Current Ratio	0.76	1.08	1.35	1.43	1.77	4.90	7.16	9.36	8.49	11.96	12.28	11.59
Quick Ratio	0.74	1.05	1.31	1.40	1.73	4.79	6.89	9.09	8.21	11.51	11.87	11.40
Working Capital	-6.77M	2.42M	10.70M	16.59M	28.01M	59.34M	71.76M	83.74M	70.29M	79.14M	87.61M	96.19M
Leverage & Debt
Debt to Equity	-4.32	10.73	2.73	2.09	1.21	0.88	0.23	0.57	0.14	0.09	0.09	0.10
Interest Coverage TTM	-14.83	-14.31	-14.22	-13.69	-16.56	-25.53	-39.28	-87.68	-95.15	-91.37	-89.93	-232.74
Debt Ratio	1.30	0.91	0.73	0.68	0.55	0.47	0.14	0.36	0.11	0.08	0.08	0.08
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-1.09	-1.15	-1.22	-1.32	-1.23	-1.37	-1.32	-1.30	-3.68	-3.61	-3.58	-6.37
Free Cash Flow Per Share TTM	-0.88	-0.97	-0.93	-1.04	-0.98	-0.90	-0.92	-0.94	-0.92	-0.94	-0.88	-0.60
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-	-	-	-100.00%	-100.00%	-100.00%
Net Income Growth (1Y)	-9.09%	-14.07%	-5.64%	3.78%	-65.67%	-61.17%	-62.18%	-75.78%	28.30%	39.68%	45.61%	1,058.35%
EPS Growth (1Y)	-11.14%	-15.92%	-7.72%	1.54%	-66.54%	-62.14%	-63.09%	-79.58%	27.10%	38.28%	43.68%	-67.07%
Calculated Values
Free Cash Flow TTM	-34.80M	-38.29M	-36.64M	-40.13M	-38.01M	-34.58M	-35.48M	-35.50M	-34.83M	-35.50M	-33.02M	-19.10M
Net Debt	3.78M	4.77M	6.62M	-12.32M	-12.86M	6.50M	4.74M	-11.90M	-18.60M	-76.72M	-87.36M	-98.74M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-02-27Sale

Owner: Chevallard, Daniel R.

Title: CFO and COO

Shares: 3,405

Price/Share: $0.73

Value: $2,485.65

Shares Owned: 102,306

Relationship: Officer

Ownership: Direct

2023-12-01Purchase

Owner: Rothera, Mark

Title: President and CEO

Shares: 47,906

Price/Share: $0.49

Value: $23,473.94

Shares Owned: 100,000

Relationship: Director,Officer

Ownership: Direct

2023-11-28Sale

Owner: Chevallard, Daniel R.

Title: CFO and COO

Shares: 3,720

Price/Share: $0.50

Value: $1,860.00

Shares Owned: 98,822

Relationship: Officer

Ownership: Direct

2023-08-28Sale

Owner: Chevallard, Daniel R.

Title: CFO and COO

Shares: 3,512

Price/Share: $1.45

Value: $5,092.40

Shares Owned: 95,653

Relationship: Officer

Ownership: Direct

2023-05-25Sale

Owner: Chevallard, Daniel R.

Title: CFO and COO

Shares: 3,635

Price/Share: $1.42

Value: $5,161.70

Shares Owned: 92,277

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-02-27	Chevallard, Daniel R.	Officer	CFO and COO	Direct	Sale	3,405	0.73	$2,485.65	102,306	4
2023-12-01	Rothera, Mark	Director,Officer	President and CEO	Direct	Purchase	47,906	0.49	$23,473.94	100,000	4
2023-11-28	Chevallard, Daniel R.	Officer	CFO and COO	Direct	Sale	3,720	0.50	$1,860.00	98,822	4
2023-08-28	Chevallard, Daniel R.	Officer	CFO and COO	Direct	Sale	3,512	1.45	$5,092.40	95,653	4
2023-05-25	Chevallard, Daniel R.	Officer	CFO and COO	Direct	Sale	3,635	1.42	$5,161.70	92,277	4
2023-02-27	Rojkjaer, Lisa	Officer	Chief Medical Officer	Direct	Sale	2,156	1.68	$3,622.08	48,087	4
2023-02-27	Chevallard, Daniel R.	Officer	CFO and COO	Direct	Sale	3,599	1.68	$6,046.32	89,023	4
2022-11-28	Chevallard, Daniel R.	Officer	CFO and COO	Direct	Sale	3,532	2.72	$9,607.04	85,733	4
2022-11-28	Rojkjaer, Lisa	Officer	Chief Medical Officer	Direct	Sale	2,116	2.72	$5,755.52	46,116	4
2022-08-26	Chevallard, Daniel R.	Officer	CFO and COO	Direct	Sale	3,655	4.02	$14,693.10	82,376	4
2022-08-26	Rojkjaer, Lisa	Officer	Chief Medical Officer	Direct	Sale	2,190	4.01	$8,781.90	44,105	4
2022-08-26	Royston, Ivor	Director,Officer	CEO & President	Direct	Sale	13,379	4.01	$53,649.79	612,770	4
2022-05-26	Chevallard, Daniel R.	Officer	CFO and COO	Direct	Sale	3,596	1.90	$6,832.40	79,142	4
2022-05-26	Rojkjaer, Lisa	Officer	Chief Medical Officer	Direct	Sale	2,154	1.90	$4,092.60	42,168	4
2022-05-26	Royston, Ivor	Director,Officer	CEO & President	Direct	Sale	13,162	1.90	$25,007.80	600,930	4
2022-02-28	Royston, Ivor	Director,Officer	CEO & President	Direct	Sale	14,635	2.78	$40,685.30	588,873	4
2022-02-28	Rojkjaer, Lisa	Officer	Chief Medical Officer	Direct	Sale	2,395	2.78	$6,658.10	40,195	4
2022-02-28	Chevallard, Daniel R.	Officer	CFO and COO	Direct	Sale	3,998	2.78	$11,114.44	75,849	4
2021-11-29	-	Director,Officer	CEO & President	Direct	Sale	15,833	4.82	$76,315.06	571,289	4
2021-11-29	-	Officer	CFO and COO	Direct	Sale	4,325	4.82	$20,846.50	72,958	4
2021-11-29	Rojkjaer, Lisa	Officer	Chief Medical Officer	Direct	Sale	2,591	4.82	$12,488.62	38,463	4
2021-11-15	Royston, Ivor	Director,Officer	CEO & President	Direct	Purchase	8,000	5.56	$44,480.00	548,599	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2024-12-31

8.57%

Inst. Shares: 3,391,371

Shares Outstanding: 39,574,070

2024-09-30

13.74%

Inst. Shares: 5,437,617

Shares Outstanding: 39,574,070

2024-06-30

22.77%

Inst. Shares: 8,973,958

Shares Outstanding: 39,404,975

2024-03-31

23.32%

Inst. Shares: 9,171,291

Shares Outstanding: 39,323,964

2023-12-31

24.54%

Inst. Shares: 9,477,399

Shares Outstanding: 38,624,462

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2024-12-31	3,391,371	39,574,070	8.57%
2024-09-30	5,437,617	39,574,070	13.74%
2024-06-30	8,973,958	39,404,975	22.77%
2024-03-31	9,171,291	39,323,964	23.32%
2023-12-31	9,477,399	38,624,462	24.54%
2023-09-30	9,443,369	38,683,858	24.41%
2023-06-30	9,644,614	38,560,376	25.01%
2023-03-31	11,798,246	38,458,837	30.68%
2022-12-31	11,457,984	37,790,981	30.32%
2022-09-30	12,354,625	37,705,517	32.77%
2022-06-30	11,372,477	37,599,244	30.25%
2022-03-31	13,068,009	37,535,874	34.81%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Viracta Therapeutics, Inc. (VIRX) — SEC Financial Statements & Analysis

Viracta Therapeutics, Inc. (VIRX) is a pharmaceutical preparations company, incorporated in DE. Viracta Therapeutics, Inc. trades on None as: VIRX. Based on its latest SEC filing (Form 10-Q, period ending 2024-09-30), Viracta Therapeutics, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of -4.32x. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: -4.32x

Data as of 2024-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Viracta Therapeutics, Inc. in?

Viracta Therapeutics, Inc. (VIRX) operates in the Pharmaceutical Preparations industry.

What exchange does VIRX trade on?

Viracta Therapeutics, Inc. (VIRX) trades on the None.

Where is Viracta Therapeutics, Inc. incorporated?

Viracta Therapeutics, Inc. is incorporated in DE.